Delving into the Latest Updates on Alprazolam with Synapse

Overview

Basic Info

SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care.

Drug Type

Small molecule drug

Synonyms

8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002

+ [19]

Target

DOCK5 x GABAA receptor

Action

inhibitors, agonists

Mechanism

DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

DyssomniasCatatoniaDepressive Disorder+ [7]

Inactive Indication

Epilepsies, MyoclonicMild asthmaPanic

Originator Organization

Takeda Pharmaceutical Co., Ltd.Upjohn Pharmaceuticals Ltd.

Active Organization

Alexza Pharmaceuticals, Inc.Unimed Pharmaceutical, Inc.UCB Pharma SA

+ [6]

Inactive Organization

VIATRIS Pharmaceuticals Ltd.

Sandoz Group AGTeva Pharmaceuticals USA, Inc.

+ [4]

License Organization

Alexza Pharmaceuticals, Inc.

Lee's Pharmaceutical Holdings Ltd.

Engage Therapeutics, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (16 Oct 1981),

Anxiety DisordersPanic Disorder

RegulationBreakthrough Therapy (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC17H13ClN4

InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N

CAS Registry28981-97-7

研究健康研究参与者餐后单次口服受试制剂阿普唑仑片（广东南国药业有限公司，规格：0.4mg）与参比制剂阿普唑仑片（商品名：Solanax®；ヴィアトリス製薬株式会社，规格：0.4mg）在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在餐后状态下给药时的生物等效性，观察受试制剂和参比制剂在健康研究参与者中的安全性。

[Translation]

This study investigates whether there are differences in the absorption rate and extent between a single oral dose of the test formulation alprazolam tablets (Guangdong Nanguo Pharmaceutical Co., Ltd., specification: 0.4 mg) and the reference formulation alprazolam tablets (trade name: Solanax®; Viatris Pharmaceutical Co., Ltd., specification: 0.4 mg) after a meal in healthy study participants. It also evaluates the bioequivalence of the test and reference formulations when administered after a meal and observes their safety in healthy study participants.

Start Date31 Jan 2026

Sponsor / Collaborator

Guangdong Nanguo Pharmaceutical Co. Ltd.

CTR20260136

/ CompletedNot Applicable

中国健康研究参与者空腹状态下单次口服阿普唑仑片的单中心、开放、随机、两制剂、两序列、两周期、双交叉人体生物等效性试验。

[Translation] A single-center, open-label, randomized, two-formulation, two-sequence, two-cycle, double-crossover human bioequivalence trial of alprazolam tablets administered orally to participants in the China Health Study under fasting conditions.

研究健康研究参与者空腹单次口服受试制剂阿普唑仑片（广东南国药业有限公司，规格：0.4mg）与参比制剂阿普唑仑片（商品名：Solanax®；ヴィアトリス製薬株式会社，规格：0.4mg）在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在空腹状态下给药时的生物等效性，观察受试制剂和参比制剂在健康研究参与者中的安全性。

[Translation]

This study investigates whether there are differences in the absorption rate and extent between the test formulation alprazolam tablets (Guangdong Nanguo Pharmaceutical Co., Ltd., specification: 0.4 mg) and the reference formulation alprazolam tablets (trade name: Solanax®; Viatris Pharmaceutical Co., Ltd., specification: 0.4 mg) administered orally to healthy study participants on an empty stomach. It also evaluates the bioequivalence of the test and reference formulations when administered on an empty stomach and observes their safety in healthy study participants.

Start Date30 Jan 2026

Sponsor / Collaborator

Guangdong Nanguo Pharmaceutical Co. Ltd.

100 Clinical Results associated with Alprazolam

Login to view more data

100 Translational Medicine associated with Alprazolam

Login to view more data

100 Patents (Medical) associated with Alprazolam

Login to view more data

4,155

Literatures (Medical) associated with Alprazolam

01 Aug 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Isolation and identification of the designer benzodiazepine cyclopropylflualprazolam in pressed candies marketed for sleep improvement

Article

Author: Liu, Xiaopu ; Xiang, Xinhua ; Ge, Xiaowei ; Zhao, Lihong ; Dong, Peizhi

A novel alprazolam analog was detected as an illegal additive in pressed candies marketed for sleep improvement using high-performance liquid chromatography (HPLC)-diode array detection (DAD). The compound was further isolated and purified via semi-preparative liquid chromatography, and its chemical structure was elucidated through high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy. The compound was identified as cyclopropylflualprazolam. Since alprazolam is a psychotropic controlled substance, this finding has garnered significant attention from regulatory authorities. It is recommended that cyclopropylflualprazolam be included in the screening list of prohibited substances in functional foods.

01 Aug 2026·ENVIRONMENTAL POLLUTION

The occurrence and removal of antibiotic residues and antibiotic resistance genes in the largest European constructed wetland at Orhei (Moldova)

Article

Author: Valdes, Maria Eugenia ; Dziewit, Lukasz ; Rodriguez-Mozaz, Sara ; Borrego, Carles M ; Ferdohleb, Alina ; Todiras, Mihail ; Iaconi, Oana-Simina ; Wolacewicz, Mikolaj ; Decewicz, Przemyslaw

Constructed wetlands (CWs) are increasingly promoted as low-cost, nature-based solutions for wastewater treatment, particularly in low- and middle-income countries (LMICs), yet their performance in removing pharmaceutical compounds, antibiotic resistance genes (ARGs), and bacterial pathogens remains insufficiently characterized under real-field-scale conditions. Here, we investigated the fate of pharmaceutical compounds (including antibiotic residues), wastewater bacterial communities, and the associated ARGs in the largest European passive treatment system, the vertical-flow CW of Orhei (Moldova), serving nearly 26,000 inhabitants. Metagenomic profiling revealed 783 bacterial families, with a reduction from 33 families in raw sewage to 25 in the final effluent and clear enrichment of autochthonous wetland taxa. A total of 150 ARG types conferring resistance to 16 antibiotic classes were detected. The cumulative ARG load decreased by approximately 78% from influent to effluent. ARGs conferring resistance to fosfomycin, nitroimidazoles, rifamycins, streptothricin, oxazolidinones, and pleuromutilins were not detected in the final effluent, suggesting effective removal to below the detection limit of the applied metagenomic method, while sulfonamide resistance genes (sul1, sul2) persisted across all stages. Out of 29 antibiotic residues analyzed, 13 (including two sulfamethoxazole metabolites) were detected, together with 14 non-antibiotic pharmaceuticals (out of 30 residues analyzed). The removal of individual antibiotics ranged between 85 and 100%, and for other pharmaceuticals between 34 and 100%, although some compounds (e.g., carbamazepine, 10,11-epoxycarbamazepine, alprazolam) showed negative removals. Environmental risk assessment (risk quotients, RQ) indicated no significant risk to freshwater biota (RQ < 0.1) for all detected compounds in the treated effluent. Results demonstrated that a large-scale CW in the LMIC context can substantially reduce antibiotic residues and ARGs, supporting its role as an effective, nature-based component of One Health-oriented wastewater management.

01 Jul 2026·FORENSIC SCIENCE INTERNATIONAL

Advantage of analysing drug paraphernalia in cause-of-death investigations

Article

Author: Jylhä, Antti ; Kivinen, Anssi ; Ojanperä, Ilkka ; Pelander, Anna ; Kriikku, Pirkko ; Ketola, Raimo A

In the current poly-drug use context, the contribution of each detected drug to the cause of death in a fatal poisoning may be difficult to assess. In this study, we aimed to investigate whether the analysis of drug paraphernalia found at the death scene could assist in the cause-of-death determination. Over a period of about four years, drug paraphernalia were analysed whenever paraphernalia was available for the analysis and a drug-related death was suspected. A total of 134 syringes and other kinds of paraphernalia were analysed in 77 death cases. Amphetamine, buprenorphine, and alprazolam were the most common findings. One single substance was detected in 51% of the analysed items, but some items contained up to 5 different substances, typically amphetamine or buprenorphine together with a benzodiazepine. Of the cases in which drug paraphernalia were analysed, in 57%, at least one detected substance was finally implicated as the cause of death in fatal poisonings, and in 14%, the detected substance was assessed as a contributing factor to death. Analysis of drug paraphernalia generated completely new drug findings in only a few cases. Comparing the results of the analysis of drug paraphernalia recovered at the death scene with the results of post-mortem toxicology allows for better understanding of circumstances of death, and in some cases enables more accurate determination of the cause of death by identifying the freshly administered drugs. In cases with new psychoactive substances, the analysis of paraphernalia can provide information that could otherwise be difficult to obtain as the concentrations in biological samples can be low.

96

News (Medical) associated with Alprazolam

30 Jun 2026

·www.einpresswire.com

Serenus Outpatient Detox Now Open in Jacksonville, FL, Offering Medically Supervised Outpatient Detox

A new medically supervised outpatient detox center opens in Jacksonville, giving Northeast Florida adults a clinical path to withdrawal care that fits life. Serenus Outpatient Detox provides safe, evidence-based outpatient detox services, letting clients receive the medical and clinical support needed while staying connected to family, work, and recovery.” — Donnie Huston, Executive Director at Serenus Outpatient Detox. JACKSONVILLE, FL, UNITED STATES, June 29, 2026 / EINPresswire.com / -- Serenus Outpatient Detox is now open in Jacksonville, Florida, bringing a new standard of medically supervised outpatient detox to Northeast Florida. Located at 11555 Central Pkwy, Suite 202, Jacksonville, FL 32224, the program provides structured, physician-overseen withdrawal care for adults seeking recovery from alcohol, opioids, benzodiazepines, stimulants, and other substances, without requiring an inpatient admission or residential stay. The program is open Monday through Friday, 7 AM to 7 PM; Saturday and Sunday, 8 AM to 2 PM, and is now accepting patients. Filling a Critical Gap in Jacksonville Drug & Alcohol Detox Serenus Outpatient Detox was founded by clinicians, counselors, and recovery advocates who identified a persistent gap in Northeast Florida's behavioral health landscape: people who needed safe, effective, medically supervised withdrawal care, but had work obligations, family responsibilities, or other circumstances that made inpatient detox impractical or simply not the right fit. Unlike residential treatment programs, Serenus provides medical detox in Jacksonville in an outpatient setting for individuals who need safe, evidence-based withdrawal care with daily medical monitoring, while continuing to live at home, work, and remain connected to their families, support systems, and everyday responsibilities. Clients visit the center daily for approximately two hours per visit. During each visit, nursing staff monitor vitals and manage withdrawal symptoms using FDA-approved medications tailored to each individual's history and medical needs. Clients also meet with a peer support specialist every day, receive weekly one-on-one sessions with a licensed substance use counselor, and participate in group programming centered on recovery, not just symptom management. Every detox protocol at Serenus is fully individualized. The clinical team builds each client's plan around their specific substance history, medical background, and recovery goals. A Full Range of Outpatient Detox Services The Jacksonville drug and alcohol detox program at Serenus treats withdrawal from a wide range of substances, including: - Alcohol, one of the most medically complex withdrawals and one the Serenus team is specifically equipped to manage safely - Opioids, including heroin, fentanyl, oxycodone, and hydrocodone - Benzodiazepines, including Xanax, Valium, Klonopin, and Ativan - Stimulants, including cocaine and methamphetamine - Prescription medications and other dependency-forming drugs Medication-assisted treatment options, including Vivitrol, are available on-site. The program also accommodates clients who are managing existing medication prescriptions from outside providers. From the first day of treatment, the Serenus team works alongside each client to develop a concrete aftercare plan, ensuring the right next step is identified and in place before the client completes the program. Serving Jacksonville & Northeast Florida Located in the Southside area of Jacksonville near Central Parkway, Serenus Outpatient Detox Jacksonville FL is accessible to individuals throughout Duval County and the broader Northeast Florida region, including Jacksonville Beach, Orange Park, Ponte Vedra, and surrounding communities. The program accepts most major insurance plans, and private-pay options are available. Serenus works closely with hospitals, primary care providers, therapists, non-profits, community partners, and behavioral health organizations throughout Northeast Florida. Providers and organizations interested in establishing a referral relationship are encouraged to reach out directly at 904-890-1442 or serenusdetox.com. For those seeking medical detox Jacksonville residents can rely on, Serenus offers a clinically rigorous, community-connected alternative to inpatient care. Grand Opening Open House: August 12 The Open House on August 12 will provide healthcare professionals, community partners, and members of the public an opportunity to tour the facility, meet the clinical team, and learn more about the medically supervised outpatient detox program at Serenus. Food and refreshments will also be provided. To RSVP for the August 12 open house, visit serenusdetox.com/open-house-rsvp. To learn more about outpatient detox Jacksonville FL services at Serenus, visit serenusdetox.com or call 904-890-1442. About Serenus Outpatient Detox is a medically supervised outpatient detox center located in Jacksonville, Florida. The program provides individualized, clinically comprehensive withdrawal care for adults seeking recovery from alcohol, opioids, benzodiazepines, stimulants, and other substances, without the need for inpatient admission. Serenus is built on the belief that safe detox and real recovery should fit inside your life. Donald Huston Serenus Outpatient Detox +1 904-890-1442 donnie@serenusdetox.com Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

15 May 2026

·www.mobihealthnews.com

OpenAI sued over alleged fatal ChatGPT drug advice

Editor's note: This article has been updated with a quote from OpenAI to MobiHealthNews. OpenAI is facing another lawsuit in California by parents alleging their son died from an accidental overdose after ChatGPT "coached him to mix Kratom and Xanax and provided an unprompted and lethal dosage recommendation." Tech Justice Law, Social Media Victims Law Center, and The Tech Accountability & Competition Project (housed at the Yale School of Law) filed the suit in San Francisco County Superior Court. The lawsuit against the tech giant was filed on behalf of Leila Turner-Scott and Angus Scott, parents of Samuel Nelson. Tech Justice Law Project claims Nelson had been receiving medical advice from ChatGPT for several months while the platform was "encouraging [him] to engage in increasingly dangerous behaviors." "Sam was also encouraged by ChatGPT to go to a dark, quiet room and was advised to take a deadly combination of a sedative (Benadryl) or benzodiazepines (Xanax) alongside a high dose of Kratom," the plaintiffs' attorneys allege. "ChatGPT failed to recognize the physical indicators that Sam was dying and did not recommend that he seek medical attention. Sam died from a fatal combination of alcohol, Xanax and Kratom." Tech Justice Law Project lawyers allege ChatGPT Health "distributed advice like a medical professional despite having no license, no training and no moral compass to do no harm" and that the platform could pose "serious risk" to consumers, claiming OpenAI is prioritizing speed over safety. OpenAI announced the release of ChatGPT Health earlier this year, which the company said combines an individual's personal health information with ChatGPT's intelligence. OpenAI said the platform aims to help people navigate the healthcare system and find answers to everyday health and wellness questions. Meetali Jain, executive director of the Tech Justice Law Project, stated in a release that OpenAI should be forced to pause its ChatGPT Health product until it is proven to be safe through rigorous scientific testing and independent oversight. "ChatGPT recommended a dangerous combination of drugs without offering even the most basic warning that the mix could be fatal. If a licensed doctor had done the same, the consequences under the law would be severe," Matthew P. Bergman, founding attorney of the Social Media Victims Law Center, said in a statement. In response to a request for comment, an OpenAI spokesperson told MobiHealthNews , "This is a heartbreaking situation, and our thoughts are with the family. These interactions took place on an earlier version of ChatGPT that is no longer available. ChatGPT is not a substitute for medical or mental healthcare, and we have continued to strengthen how it responds in sensitive and acute situations with input from mental health experts. The safeguards in ChatGPT today are designed to identify distress, safely handle harmful requests, and guide users to real-world help. This work is ongoing, and we continue to improve it in close consultation with clinicians."

07 May 2026

·www.einpresswire.com

ICAIE Releases New Infographic: The Growing Threat Posed By Illicit Trade of Counterfeit Medicines in Mexico

Diversification by Cartels into Pharmaceuticals Expands the Lucrative Illicit Trade in the Americas Drug cartels' illicit empires now include a growing dominance in the trafficking of fake medicines and counterfeit pharmaceuticals, a multi-billion illicit industry in Mexico and across the Americas.” — David M. Luna WASHINGTON, DC, UNITED STATES, May 7, 2026 / EINPresswire.com / -- ICAIE releases new May 2026 Infographic on illicit trade of counterfeit medicines in Mexico and the Americas by the drug cartels that have also been designated by the United States and Canada as Foreign Terrorist Organizations (FTOs) and Specially Designated Global Terrorists (SDGTs) for their armed violence, drug-fentanyl trafficking, illicit trade and other threats to their respective national security. The Cártel de Jalisco Nueva Generación (CJNG) and other Mexican cartels find diversification into the pharmaceutical sector very lucrative, earning hundreds of millions of dollars from fake, counterfeit, and diverted medicines. – COFEPRIS reports a 300% increase in falsified drug types since 2019. – AMIF estimates that 60% of medicines in Mexico are stolen, expired, falsified, or made without basic quality control. – A 2023 UCLA study found 1 in 3 border pharmacies sold fake meds—68% without prescriptions. – An LA Times investigation found 50%+ of opioid pills tested in Mexico were counterfeit, often containing fentanyl or meth. – Many of these fake pills often mimic Adderall, Xanax, OxyContin, and Percocet—and may contain fentanyl or xylazine. – 12 of 15 Adderall samples contained illicit substances—even in factory-sealed bottles. – In El Santuario, Guadalajara, cartels sell fake meds openly, costing the legal sector over $1B/year. – Vendors and pharmacists are often coerced into selling fakes alongside real medicines. – Many fake drugs target U.S. tourists, disguised as legitimate prescriptions. – Diverted medicines are real but sold illegally, often expired, stolen, or improperly stored. Find ICAIE May 2026 Infographic at: https://icaie.com/2026/05/illicit-trade-of-counterfeit-medicines-in-mexico-diversification-by-cartels-into- pharmaceuticals -expands-the-lucrative-illicit-trade-in-the-americas/ David Manuel Luna International Coalition Against Illicit Economies (ICAIE) email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Alprazolam

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00225	Alprazolam	N05BA12	DB00404

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dyssomnias	South Korea	Unimed Pharmaceutical, Inc.	13 Mar 2025
Catatonia	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Depressive Disorder	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Depressive Disorder	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	T’s Pharma Co., Ltd.	15 Feb 1984
Anxiety Disorders	United States	Upjohn US 2 LLC	16 Oct 1981
Panic Disorder	United States	Upjohn US 2 LLC	16 Oct 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 3	Belgium	UCB SA	30 Jan 2022
Epilepsy, Absence	Phase 3	United States	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	United States	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	United States	Alexza Pharmaceuticals, Inc.	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	Alexza Pharmaceuticals, Inc.	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	Alexza Pharmaceuticals, Inc.	07 Dec 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04802746 (Pubmed \| Pulm Pharmacol Ther)	Phase 1	Mild asthma	83	Staccato alprazolam 1 mg (Healthy)	blxztjwmmd(bcdnxqvhuv) = mmflagsury lrqlkwongt (hxoetqansx ) View more	Positive	01 Jun 2026
				Staccato alprazolam 2 mg (Healthy)	blxztjwmmd(bcdnxqvhuv) = bfabnjwjsj lrqlkwongt (hxoetqansx ) View more
NCT05626439 (P9-9.009, AAN2025)	Phase 1	Seizures	21	Staccato Alprazolam 2mg	kddhndkclu(igojtygpwm) = kthacqyrdh dcnaertdne (rxcrayhlau )	Positive	07 Apr 2025
				Oral Alprazolam 2mg	kddhndkclu(igojtygpwm) = mdbzpksioo dcnaertdne (rxcrayhlau )
NCT04782388 (UP0101, AAN2024)	Phase 1	-	-	Staccato Alprazolam 2 mg	xplgwrezsf(gwloimomoi) = AUC0-t showed a similar trend to AUCinf bzruqgycrv (fyfqpiraau ) View more	Positive	09 Apr 2024
				Staccato Placebo
NCT04970342 (PDID, CTgov)	Phase 1	-	13	Placebo (Lactose) Capsule+CBD+THC ("Sober" or Double Placebo)	wzfqleufjv(kfiewdpbeq) = jrlhecvloi bgkkjsbclo (eoiquctmzs, 5.737) View more	-	25 Jul 2023
				CBD+0.75 mg Alprazolam Capsule+THC (Active Alprazolam (Xanax), Placebo Cannabis)	wzfqleufjv(kfiewdpbeq) = mcidztwysu bgkkjsbclo (eoiquctmzs, 6.434) View more
NCT03478982 (ENGAGE-E-001, Pubmed)	Phase 2	Epilepsy	116	Staccato® alprazolam 1.0 mg	shftfhsfpl(efuggoihlg) = ifnhcscrpr pzyhmbsnvp (edbodkwpwl )	-	21 Oct 2022
				Staccato® alprazolam 2.0 mg	shftfhsfpl(efuggoihlg) = pghsgruzft pzyhmbsnvp (edbodkwpwl )
NCT02351115 (CTgov)	Phase 2	Epilepsy	5	placebo (Inhaled Placebo)	yqhkliyshz(jeeqgemami) = yhorptkdfk djbitfmbwe (zcibnzragt, funzapkyvp - cvnxhjchci) View more	-	10 Aug 2021
				Staccato+Alprazolam (Staccato Alprazolam, 0.5 mg)	yqhkliyshz(jeeqgemami) = mnifhgnenl djbitfmbwe (zcibnzragt, aobuldsegt - cuorziqtrd) View more
NCT03478982 (StATES \| P1.5-023 \| ENGAGE-E-001, CTgov)	Phase 2	Seizures \| Epilepsy \| Epilepsies, Myoclonic	156	Staccato Alprazolam (STAP-001) (Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg))	vkgyybfzcb = grtrdemmfl dcayiqjrhv (kzzfcnmymz, thxmibttoc - uljunfnbug) View more	-	03 Feb 2021
				placebo+alprazolam (Double-blind: Placebo)	vkgyybfzcb = crikqjhaqw dcayiqjrhv (kzzfcnmymz, hqcvnemeez - cvhwynvmus) View more
NCT03297944 (CTgov)	Phase 4	Psychomotor Disorders	15	Placebo (PLC/PLC)+ZOL+PLC+Alprazolam+Zolpidem+ALC	tkzncxeida(gjgqagtzfo) = nibdigzpli chqvdafqqm (ednwuhagul, bbobyqugms - nkwciirvam) View more	-	29 Jan 2020
NCT00603980 (CTgov)	Phase 1	Drug abuse	31	placebo (Placebo)	oecyoqoljs(zihyglrxvw) = iniuddllfd cvghzziati (sjosyuepcz, 0.349) View more	-	02 Jan 2020
				Alprazolam (Oral Alprazolam 1 mg)	oecyoqoljs(zihyglrxvw) = rkaetswowl cvghzziati (sjosyuepcz, 0.349) View more
NCT00662259 (GAD, CTgov)	Phase 4	Generalized anxiety disorder	32	Xanax (Alprazolam)	qozcgzwpdx(cxtgnhozwo) = brmaflikjl ougyhuxdmy (ahiirdsfbq, .1529) View more	-	25 Jul 2019
				Placebo (Placebo)	qozcgzwpdx(cxtgnhozwo) = lhrdenomcl ougyhuxdmy (ahiirdsfbq, .1123) View more